Cited 2 times in
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2015-04-24T17:09:00Z | - |
dc.date.available | 2015-04-24T17:09:00Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104853 | - |
dc.description.abstract | PURPOSE: To assess the feasibility of administering troxacitabine, an L-nucleoside analog that is not a substrate for deoxycytidine deaminase, in combination with cisplatin, to identify pharmacokinetic interactions, and to seek preliminary evidence of antitumor activity. METHODS: Patients with advanced solid malignancies were treated with cisplatin intravenously over an hour followed by troxacitabine intravenously over 30 min on day 1 every 28 days at the following cisplatin/troxacitabine (mg/m(2)) dose levels 50/4.8, 75/4.8, 50/6.4, 75/6.4, and 75/8.0. Plasma and urine sampling were performed to characterize the pharmacokinetic parameters of troxacitabine in combination with cisplatin. RESULTS: Thirty-one patients received 77 courses of cisplatin/troxacitabine at five dose levels. Grade 4 neutropenia lasting more than 5 days and/or grade 4 thrombocytopenia were consistently experienced by minimally pretreated (MP) and heavily pretreated (HP) patients at doses exceeding 75/6.4 and 50/4.8 mg/m(2), respectively. Mean values for the volume of distribution at steady state and clearance of troxacitabine were 196-396 L and 7.2-9.8 L/h, respectively. A patient with metastatic non-small cell lung cancer experienced a 42% reduction in extent of disease for 6 months. CONCLUSIONS: The combination of cisplatin and troxacitabine produces dose-limiting myelosuppression at lower doses of troxacitabine than single agent doses. The recommended phase II doses of cisplatin/troxacitabine are 75/6.4 and 50/4.8 mg/m(2), every 4 weeks, for MP and HP patients, respectively. The addition of cisplatin did not substantially alter the pharmacokinetic behavior of troxacitabine | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 167~175 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Cytosine/administration & dosage | - |
dc.subject.MESH | Cytosine/analogs & derivatives | - |
dc.subject.MESH | Dioxolanes/administration & dosage | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Interactions | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intravenous | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasms/drug therapy* | - |
dc.subject.MESH | Neutropenia/chemically induced* | - |
dc.subject.MESH | Thrombocytopenia/chemically induced* | - |
dc.subject.MESH | Tissue Distribution | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Chia-Chi Lin | - |
dc.contributor.googleauthor | Muralidhar Beeram | - |
dc.contributor.googleauthor | Eric K. Rowinsky | - |
dc.contributor.googleauthor | Chris H. Takimoto | - |
dc.contributor.googleauthor | Chee M. Ng | - |
dc.contributor.googleauthor | Charles E. Geyer Jr | - |
dc.contributor.googleauthor | Louis J. Denis | - |
dc.contributor.googleauthor | Johann S. De Bono | - |
dc.contributor.googleauthor | Desiree Hao | - |
dc.contributor.googleauthor | Anthony W. Tolcher | - |
dc.contributor.googleauthor | Sun-Young Rha | - |
dc.contributor.googleauthor | Jacques Jolivet | - |
dc.contributor.googleauthor | Amita Patnaik | - |
dc.identifier.doi | 10.1007/s00280-009-1020-y | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 19449006 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-009-1020-y | - |
dc.subject.keyword | Cisplatin | - |
dc.subject.keyword | Troxacitabine | - |
dc.subject.keyword | Phase I | - |
dc.subject.keyword | Pharmacokinetics | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 65 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 167 | - |
dc.citation.endPage | 175 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.65(1) : 167-175, 2009 | - |
dc.identifier.rimsid | 42523 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.